Wegovy vs Zepbound: The Real Cost-Per-Pound Comparison
Sticker price alone is the wrong way to compare these two drugs. Zepbound's LillyDirect self-pay floor ($299/mo starter dose) sits close to Wegovy's NovoCare self-pay ($349/mo) - but Zepbound's SURMOUNT-1 trial reported 22.5% peak weight loss versus Wegovy's STEP-1 result of 14.9%. Below: monthly cost by channel, the actual cost-per-pound-lost math, dosing and side-effect differences, and when switching from one to the other makes sense.
Weight loss comparison (220 lbs starting weight)
% of body weight lost over 18 months, modeled from phase 3 trial data
The cost-per-pound-lost math (self-pay, 220 lb starting weight)
This is the number that actually matters for cash-pay patients: total dollars spent to reach each drug's trial-reported peak weight loss, divided by pounds lost.
| Drug | Months to peak | Total self-pay spend | Lbs lost at peak | Cost per lb |
|---|---|---|---|---|
| Wegovy | 15.7 mo | $5,462 | 32.8 lbs | $167/lb |
| Zepbound | 16.6 mo | $4,955 | 49.5 lbs | $100/lb |
Assumes continuous self-pay manufacturer pricing (NovoCare / LillyDirect) held flat through the trial-reported time-to-peak. Actual totals vary with dose-specific pricing tiers, promotional periods, and individual titration pace. See sources for trial citations.
Monthly cost by payment channel
| Channel | Wegovy | Zepbound |
|---|---|---|
| Insurance copay (typical) | $63 | $88 |
| Manufacturer self-pay | $349 | $299 |
| Branded telehealth | $329 | $499 |
| Cash retail (full WAC) | $1,349 | $1,059 |
Wegovy pros and cons
- ✓ FDA-approved specifically for weight loss
- ✓ Robust 14.9% average weight loss in STEP-1
- ✓ Wide telehealth and pharmacy availability
- ✓ Once-weekly injection (good adherence)
- ✗ High list price ($1,349/mo without coverage)
- ✗ Insurance often denies for weight loss without comorbidity
- ✗ Mild-to-moderate GI side effects common during titration
- ✗ Lower efficacy than tirzepatide-based alternatives
Zepbound pros and cons
- ✓ Highest efficacy of any FDA-approved GLP-1 (22.5% in SURMOUNT-1)
- ✓ Dual GLP-1/GIP mechanism
- ✓ LillyDirect self-pay vials starting around $349/mo for lower doses
- ✓ FDA-approved for chronic weight management
- ✗ List price still high ($1,059/mo)
- ✗ Insurance coverage varies more than for Wegovy
- ✗ GI side effects can be more pronounced at higher doses
- ✗ Periodic supply constraints during demand spikes
Switching from Wegovy to Zepbound (or the reverse)
Switch to Zepbound if:you've plateaued at Wegovy's 2.4 mg maintenance dose after a genuine 12+ week trial, your insurance covers Zepbound (or you can access LillyDirect self-pay), and you want to try the dual GLP-1/GIP mechanism for potentially more weight loss.
Switch to Wegovy if:Zepbound's GI side effects are intolerable even after slower titration, you specifically need the pen format and can't access insurance-covered Zepbound (pharmacy Zepbound at full WAC price is expensive), or your insurance covers Wegovy but denies Zepbound.
Neither, stay put if:you're still gaining weight loss on your current drug and haven't reached a genuine plateau, or you're tolerating your current drug well and the cost-per-pound math on your specific channel already favors it.
Discuss timing and any washout period with your prescriber before switching. This is educational content only, not a treatment recommendation.
Where to actually buy Wegovy or Zepbound (and the alternatives)
Manufacturer direct prices (LillyDirect, NovoCare) are usually cheapest. Updated May 2026.
| Drug | Insurance | Mfr direct | Telehealth (brand) | Telehealth (compd) | Cash retail | Get it |
|---|---|---|---|---|---|---|
| Wegovy 14.9% weight loss | $63 | $349 | $329 | $249 cheapest | $1,349 | Get →ad |
| Ozempic 11.6% weight loss | $63 | - | $399 | $199 cheapest | $998 | Get →ad |
| Wegovy (oral 25mg) 13.6% weight loss | $63 | $149 cheapest | $449 | - | $1,349 | Get →ad |
| Zepbound 22.5% weight loss | $88 | $299 cheapest | $499 | $299 cheapest | $1,059 | Get →ad |
| Mounjaro 20.9% weight loss | $88 | - | $499 | $299 cheapest | $1,069 | Get →ad |
| Saxenda 8.4% weight loss | $63 | - | $399 cheapest | - | $1,349 | Get →ad |
| Foundayo (orforglipron) 14.7% weight loss | $63 | $149 cheapest | - | - | $1,099 | Get →ad |
Frequently asked questions
Is Zepbound really better than Wegovy, or just more expensive?
Neither framing is quite right. Zepbound's SURMOUNT-1 trial reported 22.5% peak weight loss at 72 weeks versus Wegovy's STEP-1 result of 14.9% at 68 weeks - a real efficacy gap driven by tirzepatide's dual GLP-1/GIP mechanism versus semaglutide's single-receptor action. But list price alone doesn't tell you which is the better value: Zepbound's LillyDirect self-pay vials ($299/mo starter dose) are actually priced close to or below Wegovy's NovoCare self-pay ($349/mo). So for most cash-pay patients, Zepbound produces materially more weight loss for a similar or lower monthly cost - which is why the cost-per-pound-lost math (below) usually favors Zepbound even before you factor in getting there faster.
Which one is cheaper if I have insurance?
If both are covered by your specific plan, the copays are usually close - typically $25-100/mo for Wegovy and $25-150/mo for Zepbound, though your actual number depends entirely on your formulary tier. The bigger insurance question isn't which copay is lower, it's which drug your plan covers AT ALL. Wegovy has been on the market since 2021 and has broader formulary presence; Zepbound launched in 2023 and some plans are still catching up on prior-authorization criteria. Check your Summary of Benefits for both before assuming either is covered - many plans that cover one weight-loss GLP-1 explicitly exclude the other.
How much weight will I actually lose - trial numbers or something lower?
Trial numbers are population means, not guarantees. STEP-1 and SURMOUNT-1 both report averages with wide individual variance - some patients lose far more than the mean, some far less. Real-world registries (not the controlled trial setting) generally show 60-80% of trial-reported weight loss, driven by adherence gaps, slower or incomplete dose titration, and less structured lifestyle counseling than trial participants received. Applying that discount: Wegovy's real-world range is roughly 9-12% body weight, Zepbound's is roughly 13.5-18%. The relative gap between the two drugs tends to hold even as the absolute numbers come down from the trial ceiling.
What is the actual dosing and injection difference?
Both are once-weekly subcutaneous injections, but the escalation schedules and delivery formats differ. Wegovy titrates 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg over 16+ weeks in a prefilled auto-injector pen (all doses, all channels). Zepbound titrates 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg over 20+ weeks, but the FORMAT depends on how you get it: pharmacy-dispensed Zepbound (insurance or full WAC price) comes as an auto-injector pen; LillyDirect self-pay Zepbound comes as single-dose vials requiring a manual syringe draw - Lilly's explicit tradeoff for the lower self-pay price. If needle anxiety or manual dosing accuracy is a concern, factor the LillyDirect vial format into your decision, not just the price.
What about side effects - is one more tolerable than the other?
Both drugs share the same core GI side-effect profile - nausea, diarrhea, constipation, vomiting - because both work by slowing gastric emptying and suppressing appetite via GLP-1 receptor activation. Zepbound's dual GLP-1/GIP mechanism and generally faster dose escalation to a higher relative potency can produce more pronounced GI effects during titration for some patients, though this varies significantly by individual. Neither drug has a clearly superior tolerability profile in head-to-head data; anecdotal reports run in both directions. If you've already tolerated one GLP-1 poorly, that's a more useful signal for your prescriber than trial-level side-effect statistics.
Should I switch from Wegovy to Zepbound if I plateaued?
It's a common and often reasonable move, but not automatic. Plateaus can be adherence-related, dose-related (not yet at your ceiling dose), or genuinely physiological. Before switching, confirm you're at Wegovy's 2.4 mg maintenance dose and have been on it long enough (12+ weeks) for a fair trial - some patients plateau and then continue losing at the same dose with more time. If you're at max dose with a genuine plateau, switching to Zepbound's different mechanism (dual incretin vs single) is a reasonable next step and is explicitly discussed in obesity-medicine literature as a rational sequencing strategy. Discuss timing and washout with your prescriber - don't self-switch.
Can I use my Wegovy savings card on Zepbound, or vice versa?
No. Manufacturer savings cards are drug-specific and tied to the manufacturer - the Wegovy Savings Card is a Novo Nordisk program, the Zepbound Savings Card is an Eli Lilly program, and neither transfers to the other's product. If you switch drugs, you need to apply for the new manufacturer's card separately (assuming your insurance covers the new drug, since both savings cards require existing commercial coverage as an eligibility gate).
Related guides
Stay ahead of every GLP-1 development
We'll email you when something actually matters: new FDA approvals (Foundayo, CagriSema, retatrutide), pricing drops at LillyDirect/NovoCare, telehealth deals, clinical trial results, FDA recalls, and insurance policy changes. ~1-2 emails/month. No filler.